Should I buy or sell Insmed stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INSM shares. View INSM analyst ratings or view top-rated stocks .

What is Insmed's stock price target for 2024?

11 Wall Street analysts have issued 12 month target prices for Insmed's stock. Their INSM share price targets range from $36.00 to $55.00. On average, they expect the company's stock price to reach $44.64 in the next year. This suggests a possible upside of 70.0% from the stock's current price. View analysts price targets for INSM or view top-rated stocks among Wall Street analysts .

How have INSM shares performed in 2024?

Insmed's stock was trading at $30.99 at the beginning of the year. Since then, INSM stock has decreased by 15.3% and is now trading at $26.26. View the best growth stocks for 2024 here .

When is Insmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our INSM earnings forecast .

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) posted its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by $0.15. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to analyst estimates of $82.15 million. Insmed's revenue was up 41.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.20) EPS.

What ETFs hold Insmed's stock?

ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include BNY Mellon Innovators ETF (BKIV) , Virtus LifeSci Biotech Products ETF (BBP) , SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU) . Principal Healthcare Innovators ETF (BTEC) .

What guidance has Insmed issued on next quarter's earnings?

Insmed updated its FY 2024 earnings guidance on Saturday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340.0 million-$360.0 million, compared to the consensus revenue estimate of $359.5 million.

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com . Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild) , AbbVie (ABBV) , Johnson & Johnson (JNJ) , NVIDIA (NVDA) , Micron Technology (MU) , ACADIA Pharmaceuticals (ACAD) , OPKO Health (OPK) , Pfizer (PFE) , Alibaba Group (BABA) and Geron (GERN) .

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:INSM

Insmed (INSM) Stock Price, News & Analysis

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)

Free INSM Stock Alerts

$26.26

-0.56 (-2.09%)

(As of 01:33 PM ET)

Compare

Today's Range: $26.23
▼
$26.98
50-Day Range: $25.72
▼
$29.51
52-Week Range: $16.81
▼
$32.00

Volume: 1.21 million shs
Average Volume: 1.68 million shs
Market Capitalization: $3.90 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.64

Get Insmed alerts:

Insmed MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 70.0% Upside
$44.64 Price Target
Short Interest: Bearish
6.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.29
Upright™ Environmental Score
News Sentiment: 1.04
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.65) to ($3.81) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.11 out of 5 stars

Medical Sector

166th out of 930 stocks

Pharmaceutical Preparations Industry

62nd out of 428 stocks

4.5

Analyst's Opinion

Consensus Rating
Insmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Insmed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.09% of the outstanding shares of Insmed have been sold short.
Short Interest Ratio / Days to Cover
Insmed has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Insmed has recently increased by 2.26%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Insmed does not currently pay a dividend.
Dividend Growth
Insmed does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Insmed has received a 68.35% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Preclinical research services for physical health", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Insmed is -1.29.

3.4

News and Social Media Coverage

News Sentiment
Insmed has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Insmed this week, compared to 3 articles on an average week.
Search Interest
15 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Insmed insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of Insmed is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Insmed are expected to grow in the coming year, from ($4.65) to ($3.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Insmed is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Insmed is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Insmed Stock (NASDAQ:INSM)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

INSM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INSM Stock News Headlines

April 16, 2024 | americanbankingnews.com

Head to Head Survey: Daré Bioscience (NASDAQ:DARE) versus Insmed (NASDAQ:INSM)

April 13, 2024 | americanbankingnews.com

Insmed (NASDAQ:INSM) PT Raised to $40.00

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 10, 2024 | finance.yahoo.com

What Makes Insmed (INSM) a Lucrative Investment?

April 7, 2024 | americanbankingnews.com

Insmed Incorporated (NASDAQ:INSM) Receives Consensus Rating of "Buy" from Analysts

April 6, 2024 | cnn.com

Insmed Incorporated

April 5, 2024 | finanznachrichten.de

Insmed Incorporated: Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 27, 2024 | finance.yahoo.com

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 19, 2024 | markets.businessinsider.com

Strong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed’s Brensocatib

March 17, 2024 | finance.yahoo.com

INSM Apr 2024 25.000 put

March 15, 2024 | markets.businessinsider.com

Crinetics Pharmaceuticals Earns ‘Buy’ Rating on Clinical Success and Market Expansion Potential

March 13, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)

March 12, 2024 | yahoo.com

Jane Seymour Talks 'Unseenism,' Aging, Advocating for Yourself and More

March 11, 2024 | msn.com

Jane Seymour Slams Ageism Against Women: ‘It’s a Real, Really Large Issue’

March 7, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Zimmer Biomet Holdings (ZBH)

March 1, 2024 | msn.com

Jane Seymour raises awareness about 'unseenism' after she feels ignored and overlooked as she gets older

March 1, 2024 | msn.com

Jane Seymour Talks About Being ‘Unseen’ as She Ages, Says Men ‘Look Over My Head and Find the Nearest Man’ To Talk To

February 29, 2024 | prnewswire.com

Insmed To Present at Three March Conferences

February 28, 2024 | finance.yahoo.com

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

February 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Insmed on Positive Pipeline Prospects and Robust Revenue Forecasts

February 27, 2024 | msn.com

UBS Initiates Coverage of Insmed (INSM) with Buy Recommendation

February 26, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Insmed on Strong Sales and Promising Trial Outlook

February 24, 2024 | finance.yahoo.com

Insmed Full Year 2023 Earnings: EPS Misses Expectations

February 23, 2024 | markets.businessinsider.com

Buy Recommendation for Insmed: Underestimated Drug Potential and Solid Financials

February 23, 2024 | finance.yahoo.com

Insmed Incorporated (NASDAQ:INSM) Q4 2023 Earnings Call Transcript

February 23, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and BioMarin Pharmaceutical (BMRN)

See More Headlines

Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:INSM
CUSIP: N/A
CIK: 1104506
Web: www.insmed.com
Phone: 908-977-9900
Fax: 732-438-0381
Employees: 373
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $44.64
High Stock Price Target: $55.00
Low Stock Price Target: $36.00
Potential Upside/Downside: +67.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-749,570,000.00
Net Margins: -245.59%
Pretax Margin: -244.76%
Return on Equity: N/A
Return on Assets: -53.34%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.12
Quick Ratio: 3.75

Sales & Book Value

Annual Sales: $305.21 million
Price / Sales: 12.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.32) per share
Price / Book: -11.48

Miscellaneous

Outstanding Shares: 148,550,000
Free Float: 141,721,000
Market Cap: $3.96 billion
Optionable: Optionable
Beta: 0.92

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. William H. Lewis J.D. (Age 50)
Pres, CEO & Chairman
Mr. Paolo Tombesi (Age 55)
Chief Financial Officer
Ms. Christine A. Pellizzari J.D. (Age 51)
Chief Legal Officer & Corp. Sec.
Mr. Roger Adsett (Age 50)
Chief Commercial Officer
Dr. Paul D. Streck (Age 55)
Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Insmed stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INSM shares.
View INSM analyst ratings or view top-rated stocks.
What is Insmed's stock price target for 2024?: 11 Wall Street analysts have issued 12 month target prices for Insmed's stock. Their INSM share price targets range from $36.00 to $55.00. On average, they expect the company's stock price to reach $44.64 in the next year. This suggests a possible upside of 70.0% from the stock's current price.
View analysts price targets for INSM or view top-rated stocks among Wall Street analysts.
How have INSM shares performed in 2024?: Insmed's stock was trading at $30.99 at the beginning of the year. Since then, INSM stock has decreased by 15.3% and is now trading at $26.26.
View the best growth stocks for 2024 here.
When is Insmed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our INSM earnings forecast.
How were Insmed's earnings last quarter?: Insmed Incorporated (NASDAQ:INSM) posted its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by $0.15. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to analyst estimates of $82.15 million. Insmed's revenue was up 41.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.20) EPS.
What ETFs hold Insmed's stock?: ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include BNY Mellon Innovators ETF (BKIV), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Principal Healthcare Innovators ETF (BTEC).

What guidance has Insmed issued on next quarter's earnings?: Insmed updated its FY 2024 earnings guidance on Saturday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340.0 million-$360.0 million, compared to the consensus revenue estimate of $359.5 million.
What is Will Lewis' approval rating as Insmed's CEO?: 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.
What other stocks do shareholders of Insmed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).
How do I buy shares of Insmed?: Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INSM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial